Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Analysis of Pharmaceutical Joint Ventures In China

This article was originally published in PharmAsia News

Executive Summary

South Medicine Economic Research Institute of China's State FDA recently released an analysis of pharmaceutical joint ventures in the country. These organizations' market shares have been increasing steadily at the expense of local and overseas drug companies, rising from 31.67 percent in 2002 to 40.16 percent in 2006. Several key trends are observed in these collaborative businesses: 1) a move toward full proprietorship; 2) R&D setup in China; 3) a switch from prescription to OTC drugs; 4) localization of drug preparation; and 5) accelerated development of tertiary market. An overview is provided of the top 10 China pharmaceutical joint ventures, namely, Shanghai Roche, Dalian Pfizer, AstraZeneca (Wuxi), Beijing Bayer, Sanofi-Synthélabo Minsheng, Hangzhou MSD, Suzhou Lilly, Beijing Novartis, Shanghai Squibb and Jiangsu Sino-Swed. (Click here for more - Chinese Language)

You may also be interested in...

Guardant Health Expects FDA Approval Of Liquid Biopsy Test Will Strengthen Coverage, Adoption

Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.

Finance Watch: CureVac’s IPO Is Ready For Launch

Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m. 

US FDA's Hahn Promotes Provider Role In Boosting Public Confidence In COVID-19 Products

Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts